Letermovir prophylaxis and early CMV DNAemia after allogeneic hematopoietic stem cell transplantation: a real‑world study from China. (PubMed, Sci Rep) - Apr 30, 2026 - "This real‑world study describes the incidence and clinical characteristics of early CMV DNAemia in allo‑HSCT recipients receiving letermovir prophylaxis. Lower letermovir exposure and the use of high‑dose corticosteroids were more commonly observed among patients with breakthrough CMV DNAemia, highlighting clinical factors that warrant attention in this setting."
Journal • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Huachao Zhu; Juan Ren; Pengcheng He; Xiaoning Wang
|